Zenas BioPharma (NASDAQ:ZBIO) Trading 7.4% Higher - Should You Buy?

Key Points

• Zenas BioPharma shares rose 7.4% during trading, closing at $20.37, with a notable decline in trading volume.
• Wall Street Zen upgraded Zenas from a "sell" to a "hold" rating, with the stock currently holding a consensus rating of "Buy" and an average target price of $36.67.
• The company reported a quarterly loss of ($1.25) EPS, missing expectations by ($0.23).

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) shares rose 7.4% during trading on Wednesday . The stock traded as high as $20.37 and last traded at $20.37. Approximately 54,320 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 191,567 shares. The stock had previously closed at $18.96.

Analyst Ratings Changes

Separately, Wall Street Zen raised Zenas BioPharma from a "sell" rating to a "hold" rating in a report on Friday, September 5th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $36.67.

Zenas BioPharma Price Performance

The firm's 50-day moving average is $16.96. The company has a market cap of $848.52 million and a P/E ratio of -5.68.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.23).

Hedge Funds Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently made changes to their positions in ZBIO. New York State Common Retirement Fund bought a new position in shares of Zenas BioPharma in the first quarter worth about $49,000. PNC Financial Services Group Inc. boosted its holdings in shares of Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock valued at $89,000 after buying an additional 2,679 shares during the period. Sei Investments Co. acquired a new position in Zenas BioPharma during the second quarter worth $118,000. Intech Investment Management LLC boosted its holdings in Zenas BioPharma by 13.9% during the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company's stock worth $128,000 after purchasing an additional 1,607 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Zenas BioPharma by 32.3% during the second quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock worth $136,000 after purchasing an additional 3,412 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.